Search details
1.
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
N Engl J Med
; 386(6): 509-520, 2022 02 10.
Article
in English
| MEDLINE | ID: mdl-34914868
2.
Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing.
Proc Natl Acad Sci U S A
; 118(15)2021 04 13.
Article
in English
| MEDLINE | ID: mdl-33766889
3.
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.
Infection
; 51(5): 1273-1284, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-36648627
4.
Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
Antimicrob Agents Chemother
; 66(6): e0013322, 2022 06 21.
Article
in English
| MEDLINE | ID: mdl-35546110
5.
Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
Antimicrob Agents Chemother
; 66(5): e0222321, 2022 05 17.
Article
in English
| MEDLINE | ID: mdl-35491829
6.
Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
Antimicrob Agents Chemother
; 65(12): e0121621, 2021 11 17.
Article
in English
| MEDLINE | ID: mdl-34570651
7.
Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3.
J Infect Dis
; 221(9): 1398-1406, 2020 04 07.
Article
in English
| MEDLINE | ID: mdl-31175822
8.
Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention.
Antimicrob Agents Chemother
; 62(10)2018 10.
Article
in English
| MEDLINE | ID: mdl-30012772
9.
MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.
Antimicrob Agents Chemother
; 61(8)2017 08.
Article
in English
| MEDLINE | ID: mdl-28559249
10.
Derivatives of mesoxalic acid block translocation of HIV-1 reverse transcriptase.
J Biol Chem
; 290(3): 1474-84, 2015 Jan 16.
Article
in English
| MEDLINE | ID: mdl-25355312
11.
In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.
Antimicrob Agents Chemother
; 59(1): 590-8, 2015 Jan.
Article
in English
| MEDLINE | ID: mdl-25385110
12.
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).
Microbiol Spectr
; 12(3): e0356323, 2024 Mar 05.
Article
in English
| MEDLINE | ID: mdl-38299867
13.
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Infect Dis Ther
; 12(12): 2725-2743, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37995070
14.
Impact of primer-induced conformational dynamics of HIV-1 reverse transcriptase on polymerase translocation and inhibition.
J Biol Chem
; 286(34): 29575-83, 2011 Aug 26.
Article
in English
| MEDLINE | ID: mdl-21737446
15.
Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor.
Antimicrob Agents Chemother
; 56(6): 3324-35, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-22391531
16.
Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week.
J Acquir Immune Defic Syndr
; 89(2): 191-198, 2022 02 01.
Article
in English
| MEDLINE | ID: mdl-34654041
17.
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.
NEJM Evid
; 1(2): EVIDoa2100044, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-38319178
18.
Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors.
J Virol
; 84(15): 7625-33, 2010 Aug.
Article
in English
| MEDLINE | ID: mdl-20484498
19.
Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial.
Nat Med
; 27(10): 1712-1717, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34608329
20.
Safety and Pharmacokinetics of Once-Daily Multiple-Dose Administration of Islatravir in Adults Without HIV.
J Acquir Immune Defic Syndr
; 88(3): 314-321, 2021 11 01.
Article
in English
| MEDLINE | ID: mdl-34651606